Dina Ouahbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dina Ouahbi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Adèle de Masson
Service de Dermatologie Hôpital Saint Louis, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
1 shared publication - Alis Ilie
Université de Bourgogne Europe, Dijon, France
1 shared publication - Angélique Vienot
Department of medical oncology, University Hospital of Besançon, Besançon, France
1 shared publication - Anthony Bergeron
Centre Georges-François Leclerc
1 shared publication - Armand Bensussan
Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, Paris, France
1 shared publication - Baptiste Louveau
Universite Paris Cite Paris France
1 shared publication
Latest Publications
- Open Access
- 2 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2754
Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant therapy. We sought to generate a deep learning approach based on hematoxylin and eosin (H&E) or hematoxylin, eosin and saffron (HES) whole slides to predict patients’ outcome, compare these new entities with known molecular subtypes and question their biological significance; Methods: We used as a training set a retrospective private cohort of 206 patients treated by surgery for PDAC cancer and a validation cohort of 166 non-metastatic patients from The Cancer Genome Atlas (TCGA) PDAC project. We estimated a multi-instance learning survival model to predict relapse in the training set and evaluated its performance in the validation set. RNAseq and exome data from the TCGA PDAC database were used to describe the transcriptomic and genomic features associated with deep learning classification; Results: Based on the estimation of an attention-based multi-instance learning survival model, we identified two groups of patients with a distinct prognosis. There was a significant difference in progression-free survival (PFS) between these two groups in the training set (hazard ratio HR = 0.72 [0.54;0.96]; p = 0.03) and in the validation set (HR = 0.63 [0.42;0.94]; p = 0.01). Transcriptomic and genomic features revealed that the poor prognosis group was associated with a squamous phenotype. Conclusions: Our study demonstrates that deep learning could be used to predict PDAC prognosis and offer assistance in better choosing adjuvant treatment.
- 2 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2754
Open AccessDeep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant therapy. We sought to generate a deep learning approach based on hematoxylin and eosin (H&E) or hematoxylin, eosin and saffron (HES) whole slides to predict patients’ outcome, compare these new entities with known molecular subtypes and question their biological significance; Methods: We used as a training set a retrospective private cohort of 206 patients treated by surgery for PDAC cancer and a validation cohort of 166 non-metastatic patients from The Cancer Genome Atlas (TCGA) PDAC project. We estimated a multi-instance learning survival model to predict relapse in the training set and evaluated its performance in the validation set. RNAseq and exome data from the TCGA PDAC database were used to describe the transcriptomic and genomic features associated with deep learning classification; Results: Based on the estimation of an attention-based multi-instance learning survival model, we identified two groups of patients with a distinct prognosis. There was a significant difference in progression-free survival (PFS) between these two groups in the training set (hazard ratio HR = 0.72 [0.54;0.96]; p = 0.03) and in the validation set (HR = 0.63 [0.42;0.94]; p = 0.01). Transcriptomic and genomic features revealed that the poor prognosis group was associated with a squamous phenotype. Conclusions: Our study demonstrates that deep learning could be used to predict PDAC prognosis and offer assistance in better choosing adjuvant treatment.
- Open Access
- 28 March 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (10) , 2329-2332
Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas
- 28 March 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (10) , 2329-2332
Open AccessTargeting TGF-β Activation in Cutaneous T-Cell Lymphomas